Martin Shkreli Thinks Jazz Pharmaceuticals Could Be Worth $20 Billion, While Mast Therapeutics Is 'Worthless'
September 12, 2016 at 11:39 AM EDT
Martin Shkreli thinks Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) is wildly undervalued. Shkreli, who appeared on ...